| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/25/2004 | CN1523979A Pharmaceutical compositions of adsorbates of amorphous drug |
| 08/25/2004 | CN1523964A Infant formula supplemented with phospholipids |
| 08/25/2004 | CN1523016A Acridine derivative and its application |
| 08/25/2004 | CN1523015A 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines |
| 08/25/2004 | CN1522699A Use of prostaglandin A1 in treatment of nerve degenerative diseases such as cerebral ischemia apoplexy |
| 08/25/2004 | CN1522697A Prevention of migraine recurrence |
| 08/25/2004 | CN1163509C RET ligand (RetL) for stimulating neural and renal growth |
| 08/25/2004 | CN1163495C Pyridine compounds, preparation method thereof and pharmaceutical compositions containing them |
| 08/25/2004 | CN1163486C Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| 08/25/2004 | CN1163475C 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivative and use as MEK inhibitor thereof |
| 08/25/2004 | CN1163267C Use of GLP-1 or analogs in treatment of stroke |
| 08/25/2004 | CN1163265C Pharmaceutical formulations of nerve growth factor |
| 08/25/2004 | CN1163231C Novel galanic formulation of meloxicam for oral administration |
| 08/24/2004 | US6780971 Compositions for inhibiting the aggregation pathway of α-synuclein |
| 08/24/2004 | US6780970 Peptides for use in the treatment and prevention of diabetes, reperfusion injuries, immunological, cardiovascular and autoimune diseases |
| 08/24/2004 | US6780968 Neurokinin-2 (nk-2) antagonists useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, asthma, or pain |
| 08/24/2004 | US6780891 Modulate opiate receptors; central nervous system disorders |
| 08/24/2004 | US6780889 Prepared by mixing gamma-hydroxybutyrate and a ph-adjusting agent in an aqueous medium |
| 08/24/2004 | US6780884 Derivating of tryptamine and analogous compounds and pharmaceutical formulations containing them |
| 08/24/2004 | US6780874 Autoimmune disease; antiinflammatory agents; antiproliferative agent |
| 08/24/2004 | US6780870 Treatment of the pain (both chronic and acute), fever and inflammation of a variety of conditions and diseases mediated by cox-2 |
| 08/24/2004 | US6780869 Selective inhibitor of cox-2; antiinflammatory agent |
| 08/24/2004 | US6780866 Analgesic composition and method |
| 08/24/2004 | US6780864 Piperazine and piperidine compounds |
| 08/24/2004 | US6780862 Such as amino-indazoles for treatment of central nervous system disorders |
| 08/24/2004 | US6780861 Azabicyclic carbamates and their use as α-7 nicotinic acetylcholine receptor agonists |
| 08/24/2004 | US6780860 For therapy of cognitive dysfunction, neurodegenerative disease, or schizophrenia |
| 08/24/2004 | US6780848 Use of GPE to protect glial cells or non-dopaminergic cells from death from neural injury or disease |
| 08/24/2004 | US6780640 Human carboxypeptidases and polynucleotides encoding the same |
| 08/24/2004 | US6780609 High bone mass gene of 1.1q13.3 |
| 08/24/2004 | US6780433 Using high-shear aqueous wet granulation with fluid-bed drying to form tablets of olanzapine having polymer coating; stability and prevents discoloration; for treatment of schizophrenia, mild anxiety, gastrointestinal disorders, and |
| 08/24/2004 | US6780409 Glutamic acid decarboxylase (GAD) based delivery system |
| 08/24/2004 | US6780400 Delivery of antiemetics through an inhalation route |
| 08/24/2004 | US6780399 Delivery of stimulants through an inhalation route |
| 08/24/2004 | CA2065051C Improved use of .beta.2 bronchodilator drugs |
| 08/24/2004 | CA2061148C Glia activating factor and its production |
| 08/19/2004 | WO2004070050A2 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
| 08/19/2004 | WO2004069999A2 Screening method |
| 08/19/2004 | WO2004069869A1 Apoptosis-inducing gene and utilization of the same |
| 08/19/2004 | WO2004069840A2 Production of tetrahydroquinoline benzofurans |
| 08/19/2004 | WO2004069838A1 Cannabinoid receptor ligands and uses thereof |
| 08/19/2004 | WO2004069837A1 Pyrazolo`1,5-a!`1,3,5!triazine derivatives as cannabinoid receptor ligands |
| 08/19/2004 | WO2004069830A1 Triazole compounds and the therapeutic use thereof |
| 08/19/2004 | WO2004069828A1 Piperidine compound and medicinal use thereof |
| 08/19/2004 | WO2004069820A1 Coumarin derivatives having an affinity for oestrogen receptors, method for the preparation thereof, and pharmaceutical compositions containing the same |
| 08/19/2004 | WO2004069813A1 Saturated quinoxaline derivatives and their use as metabotropic glutamate receptor ligands |
| 08/19/2004 | WO2004069798A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| 08/19/2004 | WO2004069339A1 Treatment for attention-deficit hyperactivity disorder |
| 08/19/2004 | WO2004069258A2 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma |
| 08/19/2004 | WO2004069257A1 Benzo (1,2,5) thiadiazole als crf-antagonisten |
| 08/19/2004 | WO2004069252A1 Cabergoline for the prophylactic treatment of migraine |
| 08/19/2004 | WO2004069246A1 Drug compositions comprising inhibitors of cholinesterase for treating senile dementia |
| 08/19/2004 | WO2004069182A2 Active immunization to generate antibodies to soluble a-beta |
| 08/19/2004 | WO2004069176A2 Polymer conjugates of mutated neublastin |
| 08/19/2004 | WO2004069142A2 Anti-candida agents for the treatment of prion diseases |
| 08/19/2004 | WO2004058773A9 Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
| 08/19/2004 | WO2004055201A3 Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| 08/19/2004 | WO2004024150A3 Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression |
| 08/19/2004 | WO2004014902A8 Compounds having an activity at metabotropic glutamate receptors |
| 08/19/2004 | WO2003094853A3 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 08/19/2004 | WO2003092688A3 Heterocyclic derivatives as opioid modulators |
| 08/19/2004 | WO2003088958A3 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease |
| 08/19/2004 | WO2003053364A3 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 |
| 08/19/2004 | WO2003049702A8 Vanilloid receptor ligands and their use in treatments |
| 08/19/2004 | WO2003037260A3 Methods and compositions for treating parkinson's disease |
| 08/19/2004 | WO2003032912A8 Treatment of cns disorders using cns target modulators |
| 08/19/2004 | WO2003025149A8 Cell populations which co-express cd49c and cd90 |
| 08/19/2004 | WO2002089778A3 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| 08/19/2004 | US20040163136 SEL-12 related methods |
| 08/19/2004 | US20040162433 Lipoxin A4 analogs |
| 08/19/2004 | US20040162430 Branched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT 1A activity |
| 08/19/2004 | US20040162426 TNF (tumor necrosis factor); for treating conditions such as rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration; tumor metastasis or invasion; periodontal disease and bone disease |
| 08/19/2004 | US20040162422 adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis |
| 08/19/2004 | US20040162355 Methods of treating and preventing cerebral function disorders using sibutramine metabolites |
| 08/19/2004 | US20040162348 Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
| 08/19/2004 | US20040162334 administering enantiomorphs comprising (Z(+-)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride), as serotonin and adrenergic uptake inhibitors, with side effect reduction; antidepressants |
| 08/19/2004 | US20040162332 serotonin receptor ligands such as 6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1H-carbazol-3-amine, used for prophylaxis of anxiety, depression, schizophrenia, Alzheimer's disease, panic, phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy and nervous system disorders |
| 08/19/2004 | US20040162324 Thienylazolylalkoxyethanamines, their preparation and their application as medicaments |
| 08/19/2004 | US20040162316 Combination treatment for alcoholism and alcohol dependence |
| 08/19/2004 | US20040162314 Enzyme inhibitors of phosphordiesterase 4 having minimal side effects; antiinflammatory agents; antiallergens; asthma; neurodegenerative disorders; antidiabetic agents; pain; anti-tumor, -carcinogenic and -arthritic agents |
| 08/19/2004 | US20040162313 Heterocyclic derivatives |
| 08/19/2004 | US20040162312 NMDA NR2B antagonists for treatment |
| 08/19/2004 | US20040162305 Ester derivative of 1,4-disubstituted piperdine compounds; For therapy of pain |
| 08/19/2004 | US20040162304 Estrogen receptor modulators |
| 08/19/2004 | US20040162299 Substituted quinazolines and analogs and the use thereof |
| 08/19/2004 | US20040162297 For manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea |
| 08/19/2004 | US20040162294 Therapeutic use of selective PDE10 inhibitors |
| 08/19/2004 | US20040162291 For therapy of cardiovascular disorders and erectile dysfunction |
| 08/19/2004 | US20040162290 For therapy of cancer, benign prostatic hypertrophy or myoma of the uterus, endometriosis, polycystic ovarian disease, uterine fibroids or precocious puberty, lupus erythematosis, irritable bowel syndrome, premenstrual syndrome, hirsutism |
| 08/19/2004 | US20040162287 Substituted cyclohexane-1,4-diamine compounds |
| 08/19/2004 | US20040162274 Inhibition of steroid synthesis by use of progesterone or a progesterone receptor agonist |
| 08/19/2004 | US20040162254 Antiviral oligonucleotides targeting HSV and CMV |
| 08/19/2004 | US20040162253 Administering pharmacologically acceptable oligonucleotide at least 10 nucleotides in length, wherein the anti-HBV activity of oligonucleotide occurs principally by a non-sequence complementary mode of action |
| 08/19/2004 | US20040162246 Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same |
| 08/19/2004 | US20040161449 Formulation and method for reduction of stress in meat-producing animals |
| 08/19/2004 | US20040161414 Method of curing injured spinal cord and therapeutic agents for that |
| 08/19/2004 | US20040161385 Delivery of beta-blockers through an inhalation route |
| 08/19/2004 | DE20220917U1 Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden Compositions to prevent the misuse of opioids |
| 08/19/2004 | DE10305739A1 New indolyl-substituted benzofuran derivatives, are 5-HT(1A) agonists and 5-HT reuptake inhibitors useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents |
| 08/19/2004 | DE10305212A1 Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom Use of the sgk gene family for the diagnosis and treatment of cataract and glaucoma |